Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:GSK
gptkb:hepatitis_B_vaccine |
| gptkbp:approves |
gptkb:1989
gptkb:United_States |
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase III trials
post-exposure prophylaxis pre-exposure prophylaxis |
| gptkbp:contraindication |
severe allergic reaction to vaccine components
moderate to severe illness breastfeeding (consult healthcare provider) pregnancy (consult healthcare provider) |
| gptkbp:criteria |
gptkb:battle
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
gptkb:item
3 doses not routinely recommended 0, 1, 6 months |
| https://www.w3.org/2000/01/rdf-schema#label |
Engerix-B
|
| gptkbp:indication |
immunocompromised individuals
high-risk populations healthcare workers travelers to endemic areas chronic liver disease patients infants born to infected mothers |
| gptkbp:ingredients |
recombinant hepatitis B surface antigen
|
| gptkbp:is_available_in |
multiple countries
|
| gptkbp:is_effective_against |
over 90% in healthy individuals
|
| gptkbp:is_used_for |
hepatitis B prevention
|
| gptkbp:is_vulnerable_to |
high
healthcare professional refrigerated long-lasting immunity ongoing studies for long-term effects subunit vaccine childhood vaccination schedule adult vaccination schedule post-vaccination observation recommended based on recombinant DNA technology deltoid muscle for adults studies on combination vaccines two muscle sites for infants |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:marketed_as |
gptkb:Engerix-B
|
| gptkbp:safety_features |
generally safe
|
| gptkbp:side_effect |
rare
fatigue headache fever pain at injection site |
| gptkbp:suitable_for |
gptkb:CDC
gptkb:WHO |
| gptkbp:target_audience |
gptkb:Person
adults infants |
| gptkbp:type |
gptkb:recombinant_vaccine
|